This plan is set to position Alnylam Pharmaceuticals for sustainable growth, focusing on near- and mid-term opportunities from the siRNA platform, aiming to maintain profitability and advance innovative medicines for rare genetic diseases.
Sarepta Therapeutics also provided updates on label revisions for ELEVIDYS, the first approved gene therapy for Duchenne muscular dystrophy, alongside preliminary financial results for the quarter ended June 30, 2025.
“Faced with environmental changes, we have decided to act decisively, implementing a focused strategy to ensure Sarepta Therapeutics remains a vibrant, financially enduring, patient-centric organization dedicated to improving the lives of those with rare genetic diseases,” said Doug Ingram, CEO of Sarepta Therapeutics.
